Treffer 1 - 6 von 6 für Suche 'Zannori, Cristina', Suchdauer: 0,47s Treffer weiter einschränken
  1. 1
    3194: LA-NSCLC: clinical outcomes and comparison of 2-weekly versus 4-weekly durvalumab consolidation

    3194: LA-NSCLC: clinical outcomes and comparison of 2-weekly versus 4-weekly durvalumab consolidation von Arcidiacono, Fabio, Anselmo, Paola, Casale, Michelina, Zannori, Cristina, Trippa, Fabio

    Veröffentlicht in Radiotherapy and oncology

    Volltext
    Artikel

    Zu den Favoriten
    Gespeichert in:
  2. 2
    3232: Five-Year survival and safety outcomes from the START-NEW-ERA non-randomised phase II trial

    3232: Five-Year survival and safety outcomes from the START-NEW-ERA non-randomised phase II trial von Arcidiacono, Fabio, Anselmo, Paola, Casale, Michelina, Zannori, Cristina, Loreti, Fabio, Enrico, Benedetta, Tassi, Valentina, Italiani, Marco, Maranzano, Ernesto, TRIPPA, Fabio

    Veröffentlicht in Radiotherapy and oncology

    Volltext
    Artikel

    Zu den Favoriten
    Gespeichert in:
  3. 3
    STereotactic Ablative RadioTherapy in NEWly Diagnosed and Recurrent Locally Advanced Non-Small Cell Lung Cancer Patients Unfit for ConcurrEnt RAdio-Chemotherapy: Early Analysis of the START-NEW-ERA Non-Randomised Phase II Trial

    STereotactic Ablative RadioTherapy in NEWly Diagnosed and Recurrent Locally Advanced Non-Small Cell Lung Cancer Patients Unfit for ConcurrEnt RAdio-Chemotherapy: Early Analysis of... von Arcidiacono, Fabio, Anselmo, Paola, Casale, Michelina, Zannori, Cristina, Ragusa, Mark, Mancioli, Francesco, Marchetti, Giovanni, Loreti, Fabio, Italiani, Marco, Bracarda, Sergio, Maranzano, Ernesto, Trippa, Fabio


    Volltext
    Artikel

    Zu den Favoriten
    Gespeichert in:
  4. 4
    First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817

    First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817 von Ready, Neal E, Audigier-Valette, Clarisse, Goldman, Jonathan W, Felip, Enriqueta, Ciuleanu, Tudor-Eliade, Rosario García Campelo, María, Jao, Kevin, Barlesi, Fabrice, Bordenave, Stéphanie, Rijavec, Erika, Urban, Laszlo, Aucoin, Jean-Sébastien, Zannori, Cristina, Vermaelen, Karim, Arén Frontera, Osvaldo, Curioni Fontecedro, Alessandra, Sánchez-Gastaldo, Amparo, Juan-Vidal, Oscar, Linardou, Helena, Poddubskaya, Elena, Spigel, David R, Ahmed, Samreen, Maio, Michele, Li, Sunney, Chang, Han, Fiore, Joseph, Acevedo, Angelic, Paz-Ares, Luis


    Volltext
    Artikel

    Zu den Favoriten
    Gespeichert in:
  5. 5
    Efficacy of Brentuximab-Vedotin (BV) in Peripheral T-Cell Lymphomas (PTCLs) Other Than Anaplastic Large Cell Lymphoma (ALCL)

    Efficacy of Brentuximab-Vedotin (BV) in Peripheral T-Cell Lymphomas (PTCLs) Other Than Anaplastic Large Cell Lymphoma (ALCL) von Zannori, Cristina, Martiniani, Roberta, Ascani, Stefano, Liberati, Fabrizio, Rauco, Annamaria, Genua, Angelo, Liberati, Anna Marina

    Veröffentlicht in Blood

    Volltext
    Artikel

    Zu den Favoriten
    Gespeichert in:
  6. 6
    Could thymomectomy be a reasonable option for non-myasthenic thymoma patients?

    Could thymomectomy be a reasonable option for non-myasthenic thymoma patients? von Tassi, Valentina, Ceccarelli, Silvia, Zannori, Cristina, Gili, Alessio, Daddi, Niccolò, Bellezza, Guido, Ascani, Stefano, Liberati, Anna Marina, Puma, Francesco

    Veröffentlicht in Journal of thoracic disease

    Volltext
    Artikel

    Zu den Favoriten
    Gespeichert in:

Suchwerkzeuge: